LY4213663

Phase 1Small molecule

Eli Lilly

LY4213663 is one of 10 small molecule programs targeting Rheumatoid Arthritis (RA). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid Arthritis (RA)Recruiting

Rheumatoid Arthritis (RA)Phase 1

Recruiting

Competition

Competitive Landscape

10 competitors in Rheumatoid Arthritis (RA)

#DrugCompanyPhaseTrials

TLL-018

HHangzhou Highlightll Pharmaceutical Co., Ltd

Phase 2

1 2

Trexall

Jazz Pharmaceuticals

Preclinical

1 3

Anti-CD19 CAR-T Cells

TThe Children's Hospital of Zhejiang University School of Medicine

Phase 1

1 4

JAB-8263

JJacobio Pharmaceuticals Co., Ltd.

Phase 2

1 5

Rapcabtagene Autoleucel

Novartis

Preclinical

1 6

Allogeneic NK Cells

AArtiva Biotherapeutics, Inc.

Phase 2

1 7

Lmy-922

LLuminary Therapeutics

Phase 1

1 8

LY4213663

Eli Lilly

Phase 1

1 9

F8IL10

PPhilogen S.p.A.

Phase 1

1 10

Conventional Synthetic DMARD

SSecondWave Systems Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Rheumatoid Arthritis (RA)

NCT07258849

Clinical

Trials by Indication[1]

Rheumatoid Arthritis (RA)1 trial

A Phase 1, Multicenter, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single- and Multiple-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4213663 in Healthy Participants, and Two Open-Label, Multiple-Dose Evaluations of LY4213663 in Patients With Rheumatoid Arthritis.

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT07258849·141 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LY4213663. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY4213663 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY4213663. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

LY4213663

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Rheumatoid Arthritis (RA)1 trial

References

Drug Info

Quick Facts

Related News